Diagnosis of unilateral renovascular hypertension: comparative effect of intravenous enalaprilat and oral captopril.
The effectiveness of 2 angiotensin converting enzyme inhibitors, intravenous enalaprilat and oral captopril, in stimulating renin secretion was compared in 47 hypertensive patients with suspected renovascular hypertension. Both inhibitors were more effective stimuli to renin secretion than head-up tilting of the patient. In patients with unilateral renovascular hypertension single doses of angiotensin converting enzyme inhibitors increased the renal venous renin ratio compared to the recumbent ratio. This therapy reduced the number of false negative studies more effectively than head-up tilting and was tolerated better. Contralateral suppression of renin in the unaffected kidney, an important ancillary diagnostic marker of unilateral renovascular hypertension, was preserved. No false positive studies owing to the use of angiotensin converting enzyme inhibitors acutely were apparent. Mean arterial pressure decreased by 5 minutes with intravenous enalaprilat and by 20 minutes with oral captopril, and it continued to decrease gradually for at least 2 hours. No significant syncopal symptoms were observed with either inhibitor. Plasma renin activity increased by 5 and 15 minutes with enalaprilat and captopril, respectively. Plasma aldosterone levels decreased by 10 minutes with enalaprilat and by 30 minutes with captopril, and these changes increased in magnitude during the 2 hours of observation. To achieve the maximum diagnostic effectiveness from the renal venous renin ratio, single dose angiotensin converting enzyme inhibitors warrant consideration for routine use. Intravenous enalaprilat may be preferable because of certain achievement of an effective blood level.
Tunny
T J
TJ
University Department of Medicine, Greenslopes Hospital, Brisbane, Australia.
Klemm
S A
SA
Hamlet
S M
SM
Gordon
R D
RD
D000284:Administration, Oral; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage; D004656:Enalapril / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015773:Enalaprilat; D005188:False Negative Reactions; D006801:Humans; D006978:Hypertension, Renovascular / Q000097:blood / Q000175:diagnosis*; D007262:Infusions, Intravenous; D012083:Renin / Q000097:blood / Q000378:metabolism
D000450:Aldosterone; D004656:Enalapril; D002216:Captopril; D012083:Renin; D015773:Enalaprilat